EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder: Update 2013

European Urology

Volumn 64, Issue 4, 2013, Pages 639-653

  Babjuk, Marko ^a   Burger, Maximilian ^b   Zigeuner, Richard ^c   Shariat, Shahrokh F ^d   Van Rhijn, Bas W G ^e   Compérat, Eva ^f   Sylvester, Richard J ^g   Kaasinen, Eero ^h   Böhle, Andreas ⁱ   Palou Redorta, Joan ^j   Rouprêt, Morgan ^f,k  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g EORTC Headquarters ^*  (Belgium)

^h HYVINKÄÄ HOSPITAL   (Finland)

ⁱ HELIOS AGNES KARLL HOSPITAL   (Germany)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^k SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

Bacillus Calmette Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; EAU Guidelines; Follow up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN;

ARTICLE; BLADDER BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CYSTECTOMY; CYSTOGRAPHY; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTRAVENOUS UROGRAPHY; NON MUSCLE INVASIVE BLADDER CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; URINE CYTOLOGY;

BACILLUS CALMETTE-GUERIN (BCG); BLADDER CANCER; CYSTECTOMY; CYSTOSCOPY; DIAGNOSIS; EAU GUIDELINES; FOLLOW-UP; INTRAVESICAL CHEMOTHERAPY; PROGNOSIS; TRANSURETHRAL RESECTION (TUR); UROTHELIAL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; BIOPSY; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC TECHNIQUES, UROLOGICAL; DISEASE PROGRESSION; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SOCIETIES, MEDICAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGY; UROTHELIUM;

EID: 84883813935     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.06.003     Document Type: Article

References (108)

1. W. Oosterlinck, B. Lobel, G. Jakse, P.U. Malmstrom, M. Stöckle, C. Sternberg The EAU Working Group on Oncological Urology Guidelines on bladder cancer Eur Urol 24 2002 105 112
2. Oxford Centre for Evidence-based Medicine levels of evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Accessed May 2013.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globocan 2008: Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
4. C. Bosetti, P. Bertuccio, L. Chatenoud, E. Negri, C. La Vecchia, and F. Levi Trends in mortality from urologic cancers in Europe, 1970-2008 Eur Urol 60 2011 1 15
5. J. Ferlay, G. Randi, and C. Bosetti Declining mortality from bladder cancer in Europe BJU Int 101 2008 11 19
6. M. Burger, J.W. Catto, and G. Dalbagni Epidemiology and risk factors of urothelial bladder cancer Eur Urol 63 2013 234 241
7. N.D. Freedman, D.T. Silverman, and A.R. Hollenbeck Association between smoking and risk of bladder cancer among men and women JAMA 306 2011 737 745
8. L. Rushton, S.J. Hutchings, and L. Fortunato Occupational cancer burden in Great Britain Br J Cancer 107 Suppl 1 2012 S3 S7
9. Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. UICC International Union Against Cancer, ed. 7. Hoboken, NJ, USA: Wiley-Blackwell; 2009. p. 262-5.
10. G. Sauter, F. Algaba, and M. Amin Tumours of the urinary system: non-invasive urothelial neoplasias J.N. Eble, G. Sauter, Epstein J.l. I. Sesterhenn, WHO classification of tumours of the urinary system and male genital organs 2004 IARCC Press Lyon, France
11. M. May, S. Brookman-Amissah, and J. Roigas Prognostic accuracy of individual uropathologists in non-invasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation Classifications Eur Urol 57 2010 850 858
12. B.W. van Rhijn, G.J. van Leenders, and B.C. Ooms The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading Eur Urol 57 2010 1052 1057
13. C.C. Pan, Y.H. Chang, and K.K. Chen Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases Am J Clin Pathol 133 2010 788 795
14. W. Otto, S. Denzinger, and H.M. Fritsche The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer BJU Int 107 2011 404 408
15. F. Pellucchi, M. Freschi, and B. Ibrahim Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors J Urol 186 2011 2194 2199
16. J.A. Witjes, P.M.J. Moonen, and A.G. van der Heijden Review pathology in a diagnostic bladder cancer trial Urology 67 2006 751 755
17. A. Van der Meijden, R. Sylvester, and L. Collette The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials J Urol 164 2000 1533 1537
18. B.W.G. Van Rhijn, T.H. van der Kwast, and D.M. Kakiashvili Pathological stage review is indicated in primary pT1 bladder cancer BJU Int 106 2010 206 211
19. D.L. Lamm, H.W. Herr, and G. Jakse Updated concepts and treatment of carcinoma in situ Urol Oncol 4 1998 130 138
20. C. Goessl, H.H. Knispel, and K. Millar Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 157 1997 480 481
21. J. Palou, F. Rodriguez-Rubio, and J. Huguet Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumours J Urol 174 2005 859 861
22. F. Millán-Rodríguez, G. Chéchile-Toniolo, and J. Salvador-Bayarri Upper urinary tract tumours after primary superficial bladder tumours: prognostic factors and risk groups J Urol 164 2000 1183 1187
23. B. Têtu Diagnosis of urothelial carcinoma from urine Mod Pathol 22 Suppl 2 2009 S53 S59
24. M.-P. Raitanen, R. Aine, and E. Rintala Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis Eur Urol 41 2002 284 289
25. V.B. Lokeshwar, T. Habuchi, and H.B. Grossman Bladder tumour markers beyond cytology: international consensus panel on bladder tumour markers Urology 66 Suppl 1 2005 35 63
26. O.P.J. Vrooman, and J.A. Witjes Urinary markers in bladder cancer Eur Urol 53 2008 909 916
27. B.W.G. Van Rhijn, H.G. van der Poel, and H.G. van der Kwast Cytology and urinary markers for the diagnosis of bladder cancer Eur Urol Suppl 8 2009 536 541
28. H.B. Grossman, E. Messing, and M. Soloway Detection of bladder cancer using a point-of-care proteomic assay JAMA 293 2005 810 816
29. Y. Lotan, R.S. Svatek, and N. Malats Screening for bladder cancer: a perspective World J Urol 26 2008 13 18
30. B.W. Van Rhijn, H.G. van der Poel, and T.H. van der Kwast Urine markers for bladder cancer surveillance: a systematic review Eur Urol 47 2005 736 748
31. H.B. Grossman, M. Soloway, and E. Messing Surveillance for recurrent bladder cancer using a point-of-care proreomic assay JAMA 295 2006 299 305
32. M. Babjuk, V. Soukup, and M. Pesl Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma Urology 71 2008 718 722
33. M.N. van der Aa, E.W. Steyerberg, and C. Bangma Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial J Urol 183 2010 76 80
34. D.S. Aaronson, T.J. Walsh, and J.F. Smith Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int 104 2009 506 509 discussion 509-10
35. M. Richterstetter, B. Wullich, and K. Amann The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer BJU Int 110 2012 E76 E79
36. M. Brausi, L. Collette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
37. P. Mariappan, A. Zachou, and K.M. Grigor Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience Eur Urol 57 2010 843 849
38. P. Mariappan, S.M. Finney, and E. Head Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking BJU Int 109 2012 1666 1673
39. H.W. Herr, S.M. Donat, and V.E. Reuter Management of low grade papillary bladder tumors J Urol 178 2007 1201 1205
40. A. Van der Meijden, W. Oosterlinck, and M. Brausi Significance of bladder biopsies in Ta, T1 bladder tumours: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee Eur Urol 35 1999 267 271
41. J. Palou, R.J. Sylvester, and O.R. Faba Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin Eur Urol 62 2012 118 125
42. M.U. Mungan, A.E. Canda, and E. Tuzel Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder Eur Urol 48 2005 760 763
43. J. Huguet, M. Crego, and S. Sabaté Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor Eur Urol 48 2005 53 59 discussion 59
44. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
45. G. Mowatt, J. N'Dow, and L. Vale Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis Int J Technol Assess Health Care 27 2011 3 10
46. R.O. Draga, M.C. Grimbergen, and E.T. Kok Photodynamic diagnosis (5 aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy Eur Urol 57 2010 655 660
47. E.R. Ray, K. Chatterton, and M.S. Khan Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin BJU Int 105 2010 789 794
48. M.C. Schumacher, S. Holmäng, and T. Davidsson Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study Eur Urol 57 2010 293 299
49. A. Stenzl, H. Penkoff, and E. Dajc-Sommerer Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial Cancer 117 2011 938 947
50. H.B. Grossman, A. Stenzl, and Y. Fradet Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
51. M. Miladi, M. Peyromaure, and M. Zerbib The value of a second transurethral resection in evaluating patients with bladder tumours Eur Urol 43 2003 241 245
52. R.T. Divrik, Ü. Yildirim, and F. Zorlu The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial J Urol 175 2006 1641 1644
53. A. Lopez-Beltran, P. Bassi, and M. Pavone-Macaluso Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis Eur Urol 45 2004 257 266
54. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
55. J. Fernandez-Gomez, R. Madero, and E. Solsona Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2009 2195 2203
56. J. Palou, F. Rodríguez-Rubio, and F. Millán Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors Urology 73 2009 1313 1317
57. R. Sylvester, A. van der Meijden, and J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 Suppl 1 2005 90 107
58. D.C. Chade, S.F. Shariat, and G. Godoy Clinical outcomes of primary bladder carcinoma in situ in a contemporary series J Urol 184 2010 74 80
59. M. Brausi, J.A. Witjes, and D. Lamm A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group J Urol 186 2011 2158 2167
60. C.P. Brocks, H. Büttner, and A. Böhle Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer J Urol 174 2005 1115 1118
61. W. Oosterlinck, K.H. Kurth, and F. Schröder A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder J Urol 149 1993 749 752
62. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials J Urol 171 2004 2186 2190
63. I. Berrum-Svennung, T. Granfors, and S. Jahnson A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences J Urol 179 2008 101 105
64. S. Gudjonsson, L. Adell, and F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773 780
65. C. Bouffioux, K.H. Kurth, and A. Bono Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group J Urol 153 1995 934 941
66. E. Kaasinen, E. Rintala, and P. Hellstrom Factors explaining recurrence in patients undergoing chemo-immunotherapy regimens for frequently recurring superficial bladder carcinoma Eur Urol 42 2002 167 174
67. D.A. Tolley, M.K. Parmar, and K.M. Grigor The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up J Urol 155 1996 1233 1238
68. D. Pode, Y. Alon, and A.T. Horowitz The mechanism of human bladder tumor implantation in an in vitro model J Urol 136 1986 482 486
69. J.R. Oddens, A.P. van der Meijden, and R. Sylvester One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 46 2004 336 338
70. M. Huncharek, R. McGarry, and B. Kupelnick Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis Anticancer Res 21 2001 765 769
71. R.J. Sylvester, W. Oosterlinck, and J.A. Witjes The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials Eur Urol 53 2008 709 719
72. R.J. Lammers, J.A. Witjes, and B.A. Inman The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review Eur Urol 60 2011 81 93
73. S.M. Di Stasi, A. Giannantoni, and A. Giurioli Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Lancet Oncol 7 2006 43 51
74. J.L. Au, R.A. Baladament, and M.G. Wientjes Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J Natl Cancer Inst 93 2001 597 604
75. M. Kuroda, T. Niijima, and T. Kotake Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer - The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml Eur Urol 45 2004 600 605
76. P.-U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
77. M.D. Shelley, H. Kynaston, and J. Court A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer BJU Int 88 2001 209 216
78. R.F. Han, and J.G. Pan Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials Urology 67 2006 1216 1223
79. M.D. Shelley, T.J. Wilt, and J. Court Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials BJU Int 93 2004 485 490
80. A. Böhle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95
81. M. Duchek, R. Johansson, and S. Jahnson Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-a2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study Eur Urol 57 2010 25 31
82. R. Järvinen, E. Kaasinen, and A. Sankila Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up Eur Urol 56 2009 260 265
83. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC Genito-Urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
84. A. Böhle, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression Urology 63 2004 682 686 discussion 686-7
85. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
86. J. Oddens, M. Brausi, and R. Sylvester Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
87. P.F. Shang, J. Kwong, and Z.P. Wang Intravesical bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer Cochrane Database Syst Rev 2011 CD006885
88. A.P. Van der Meijden, R.J. Sylvester, and W. Oosterlinck Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial Eur Urol 44 2003 429 434
89. H.W. Herr Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria J Urol 187 2012 435 437
90. O. Yossepowitch, S.E. Eggener, and B.H. Bochner Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients J Urol 176 2006 482 485
91. J.A. Witjes, J. Palou, and M. Soloway Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events Eur Urol Suppl 7 2008 667 674
92. J.A. Martínez-Piñeiro, N. Flores, and S. Isorna Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer BJU Int 89 2002 671 680
93. J.A. Martínez-Piñeiro, L. Martínez-Piñeiro, and E. Solsona Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242 1247
94. A. Ojea, J.L. Nogueira, and E. Solsona A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398 1406
95. R.J. Sylvester, A.P.M. van der Meijden, and J.A. Witjes Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 2005 86 92
96. E. Solsona, I. Iborra, and J.V. Ricos Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications J Urol 155 1996 895 899
97. J. Palou, J. Baniel, and L. Klotz Urothelial carcinoma of the prostate Urology 69 Suppl 2007 50 61
98. D.R. Yates, M.A. Brausi, and J.W. Catto Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer Eur Urol 62 2012 1088 1096
99. O. Nativ, J.A. Witjes, and K. Hendricksen Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin J Urol 182 2009 1313 1317
100. F.N. Joudi, B.J. Smith, and M.A. O'Donnell Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344 348
101. G. Di Lorenzo, S. Perdonà, and R. Damiano Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial Cancer 116 2010 1893 1900
102. S.P. Lerner, C.M. Tangen, and H. Sucharew Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non muscle invasive bladder cancer Urol Oncol 27 2009 155 159
103. B.L. Gallagher, F.N. Joudi, and J.L. Maymi Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy Urology 71 2008 297 301
104. G.V. Raj, H. Herr, and A.M. Serio Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer J Urol 177 2007 1283 1286
105. O.N. Gofrit, D. Pode, and A. Lazar Watchful waiting policy in recurrent Ta G1 bladder tumors Eur Urol 49 2006 303 307
106. P. Mariappan, and G. Smith A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database J Urol 173 2005 1008 1011
107. V. Soukup, M. Babjuk, and J. Bellmunt Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature Eur Urol 62 2012 290 302
108. S. Holmäng, and V. Ströck Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years? Eur Urol 61 2012 503 507